Showing Latest Articles
Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers
Cancer, 08/12/2011
Clinical Article
Raghav KPS et al. – In this cohort, a low ER/PR level (1%-5%) does not appear to have any significant impact on survival outcomes. There was a tendency for survival advantages in the ER/PR 6% to 10% is seen. Benefit of endocrine therapy in these patients is unclear.
Methods- Retrospective review
- 1257 patients were categorized according their ER/PR percentages into 3 groups, ER/PR <1% (group A), ER/PR 1% to 5% (group B), and ER/PR 6% to 10% (group C)
- Kaplan-Meier product limit method used to estimate survival outcomes
- Cox proportional hazards models used to adjust for patient and tumor characteristics
- Groups A, B, and C had 897 (71.4%), 241 (19.2%), and 119 (9.4%) patients
- After a median follow-up of 40 months there was no significant difference in 3-year recurrence-free survival (RFS): 64%, 67%, and 77% (P = .34) or OS: 79%, 81%, and 88% (P = .33) for groups A, B, and C
- ER/PR expression was not an independent predictor for RFS HR, 1.10; 95% CI, 0.86-1.39; P = .46 for group B, and HR, 0.96; 95% CI, 0.66-1.38; P = .81 for group C, compared with group A), or OS (HR, 1.11; 95% CI, 0.84-1.46; P = .46 for group B, and HR, 0.94; 95% CI, 0.63-1.42; P = .78 for group C, compared with group A)
- Endocrine therapy had no impact on survival outcomes (RFS: P = .10; OS: P = .45) among groups